Beam Therapeutics Inc. (BEAM)
US — Healthcare Sector
Automate Your Wheel Strategy on BEAM
With Tiblio's Option Bot, you can configure your own wheel strategy including BEAM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BEAM
- Rev/Share 0.4485
- Book/Share 9.4179
- PB 2.9056
- Debt/Equity 0.1567
- CurrentRatio 6.0175
- ROIC -0.4086
- MktCap 2776861843.0
- FreeCF/Share -3.4353
- PFCF -7.8808
- PE -6.7693
- Debt/Assets 0.1155
- DivYield 0
- ROE -0.4286
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BEAM | Jefferies | -- | Buy | -- | $41 | Oct. 9, 2025 |
| Upgrade | BEAM | BofA Securities | Neutral | Buy | -- | $42 | March 28, 2025 |
| Upgrade | BEAM | Scotiabank | Sector Perform | Sector Outperform | -- | $40 | March 10, 2025 |
| Upgrade | BEAM | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Jan. 29, 2025 |
| Initiation | BEAM | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
News
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
BEAM
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
Read More
About Beam Therapeutics Inc. (BEAM)
- IPO Date 2020-02-06
- Website https://www.beamtx.com
- Industry Biotechnology
- CEO John Evans
- Employees 393
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.